BioAmber Inc. has announced that Jean-Francois Huc has resigned as President and CEO and Fabrice Orecchioni, the company’s COO, has been named President, effective immediately.
In his role as COO over the past four years, Fabrice has overseen the construction, start-up and operation of the manufacturing plant in Sarnia and the management of the Mitsui JV. Fabrice has also been extensively involved in the negotiations with CJ CheilJedang for the proposed China JV.
Mr. Huc, who stepped down for personal reasons, will remain a member of the board of directors and will also assume an advisory role with the management team to help ensure a smooth transition.
Source: BioAmber
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.